Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies

 Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:
  • The partnership will focus on indications like diabetes, obesity, co morbidities including nonalcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic kidney disease
  • Evotec’s drug-discovery platform will be used in ligand-based design to produce products for patients
  • Also the Evotec’s INDiGO platform will be used by Novo, to perform IND registration through pre-clinical studies. Financial details were not disclosed
Click here to read full press release/ article | Ref: Evotec | Image:  Cyprotex

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post